Valk P E, Mathis C A, Prados M D, Gilbert J C, Budinger T F
Lawrence Berkeley Laboratory, University of California, Berkeley.
J Nucl Med. 1992 Dec;33(12):2133-7.
Positron emission tomography (PET) with the hypoxic-cell tracer [18F]fluoromisonidazole presents a possible means of noninvasively demonstrating tumor hypoxia. PET studies using this tracer were performed in three patients with malignant glioma, and in all patients the tumor was clearly seen at 5 min postinjection and initial tumor activity exceeded cortical activity. In one patient, there was no tumor retention of [18F] fluoromisonidazole and tumor activity fell while cortical activity increased, with the two tissues reaching equality at 40-50 min. The tumor-to-plasma ratio was 0.71 at 3 hr. The other two patients showed variable tumor retention of [18F]fluoromisonidazole, with tumor-to-plasma ratios of 1.10 and 1.49 at 2 and 3 hr. These results demonstrate the feasibility of using [18F]fluoromisonidazole PET to detect hypoxia in human gliomas in vivo. Clinical trials are needed to determine whether a relationship exists between [18F]fluoromisonidazole uptake and tumor radiation response.
使用乏氧细胞示踪剂[18F]氟米索硝唑的正电子发射断层扫描（PET）是一种无创显示肿瘤乏氧的可能方法。对3例恶性胶质瘤患者进行了使用该示踪剂的PET研究，所有患者在注射后5分钟时肿瘤均清晰可见，且肿瘤初始活性超过皮质活性。1例患者，[18F]氟米索硝唑未在肿瘤中潴留，肿瘤活性下降而皮质活性增加，两种组织在40 - 50分钟时达到相等。3小时时肿瘤与血浆的比值为0.71。另外2例患者[18F]氟米索硝唑在肿瘤中的潴留情况各异，2小时和3小时时肿瘤与血浆的比值分别为1.10和1.49。这些结果证明了使用[18F]氟米索硝唑PET在体内检测人脑胶质瘤乏氧的可行性。需要进行临床试验以确定[18F]氟米索硝唑摄取与肿瘤放射反应之间是否存在关联。
